Multidisciplinary approach to bariatric surgery: surgical alternative of gastric banding
2002-01-01 Gaeta, Luigi
Dietary supplement and drug use and doping knowledge and attitudes in italian young elite cyclists
2014-01-01 Loraschi, A.; Galli, N.; Cosentino, Marco
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.
2013-01-01 Tefferi, A; Rumi, E; Finazzi, G; Gisslinger, H; Vannucchi, Am; Rodeghiero, F; Randi, Ml; Vaidya, R; Cazzola, M; Rambaldi, A; Gisslinger, B; Pieri, L; Ruggeri, M; Bertozzi, I; Sulai, Nh; Casetti, I; Carobbio, A; Jeryczynski, G; Larson, Dr; Müllauer, L; Pardanani, A; Thiele, J; Passamonti, Francesco; Barbui, T.
Ruxolitinib and survival improvement in patients with myelofibrosis
2015-01-01 Passamonti, Francesco; A. M., Vannucchi; F., Cervantes; C., Harrison; E., Morra; H., Kantarjian; S., Verstovsek
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
2013-01-01 G., Barosi; R., Mesa; G., Finazzi; C., Harrison; J. J., Kiladjian; E., Lengfelder; M. F., Mcmullin; Passamonti, Francesco; A. M., Vannucchi; C., Besses; H., Gisslinger; J., Samuelsson; S., Verstovsek; R., Hoffman; A., Pardanani; F., Cervantes; A., Tefferi; T., Barbui
Use of the functional assessment of cancer therapy-anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia
2014-01-01 Ayalew, Tefferi; Stacie, Hudgens; Ruben, Mesa; Robert Peter, Gale; Srdan, Verstovsek; Passamonti, Francesco; Francisco, Cervantes; Candido, Rivera; Tom, Tencer; Zeba M., Khan
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
2013-01-01 F., Cervantes; A. M., Vannucchi; J. J., Kiladjian; H. K., Al Ali; A., Sirulnik; V., Stalbovskaya; M., Mcquitty; D. S., Hunter; R. S., Levy; Passamonti, Francesco; T., Barbui; G., Barosi; C. N., Harrison; L., Knoops; H., Gisslinger
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
2013-01-01 A., Tefferi; F., Cervantes; R., Mesa; Passamonti, Francesco; S., Verstovsek; A. M., Vannucchi; J., Gotlib; B., Dupriez; A., Pardanani; C., Harrison; R., Hoffman; H., Gisslinger; N., Kroger; J., Thiele; T., Barbui; G., Barosi
RBC-transfusion guidelines update
2012-01-01 Gale, Rp; Barosi, G; Barbui, T; Cervantes, F; Dohner, K; Dupriez, B; Gupta, V; Harrison, C; Hoffman, R; Kiladjian, Jj; Mesa, R; Mc Mullin, Mf; Passamonti, Francesco; Ribrag, V; Roboz, G; Saglio, G; Vannucchi, A; Verstovsek, S.
PDGFRB disease: right diagnosis to prolong survival
2014-01-01 Passamonti, Francesco
Novel agents in indolent lymphomas
2012-01-01 Merli, M.; Ferrario, A.; Basilico, C.; Maffioli, M.; Caramazza, D.; Appio, L.; Arcaini, L.; Passamonti, Francesco
New generation small-molecule inhibitors in myeloproliferative neoplasms
2012-01-01 Passamonti, Francesco; Maffioli, M; Caramazza, D.
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs
2012-01-01 Emanuel, R. M.; Dueck, A. C.; Geyer, H. L.; Kiladjian, J. J.; Slot, S.; Zweegman, S.; Te Boekhorst, P. A. W.; Commandeur, S.; Schouten, H. C.; Sackmann, F.; Fuentes, A. K.; Hernández Maraver, D.; Pahl, H. L.; Griesshammer, M.; Stegelmann, F.; Doehner, K.; Lehmann, T.; Bonatz, K.; Reiter, A.; Boyer, F.; Etienne, G.; Ianotto, J. C.; Ranta, D.; Roy, L.; Cahn, J. Y.; Harrison, C. N.; Radia, D.; Muxi, P.; Maldonado, N.; Besses, C.; Cervantes, F.; Johansson, P. L.; Barbui, T.; Barosi, G.; Vannucchi, A. M.; Passamonti, Francesco; Andreasson, B.; Ferarri, M. L.; Rambaldi, A.; Samuelsson, J.; Birgegard, G.; Tefferi, A.; Mesa, R. A.
Looking for familial nodular lymphocyte-predominant Hodgkin lymphoma
2013-01-01 Merli, M.; Maffioli, M.; Ferrario, A.; Passamonti, Francesco
Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
2012-01-01 Verstovsek, S; Kantarjian, Hm; Estrov, Z; Cortes, Je; Thomas, Da; Kadia, T; Pierce, S; Jabbour, E; Borthakur, G; Rumi, E; Pungolino, E; Morra, E; Caramazza, D; Cazzola, M; Passamonti, Francesco
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients.
2012-01-01 Buxhofer Ausch, V; Gisslinger, H; Thiele, J; Gisslinger, B; Kvasnicka, Hm; Müllauer, L; Frantal, S; Carobbio, A; Passamonti, Francesco; Rumi, E; Ruggeri, M; Rodeghiero, F; Randi, Ml; Bertozzi, I; Vannucchi, Am; Antonioli, E; Finazzi, G; Gangat, N; Tefferi, A; Barbui, T.
Leukemia risk models in primary myelofibrosis: an International Working Group study.
2012-01-01 Tefferi, A; Pardanani, A; Gangat, N; Begna, Kh; Hanson, Ca; Van Dyke, Dl; Caramazza, D; Vannucchi, Am; Morra, E; Cazzola, M; Pereira, A; Cervantes, F; Passamonti, Francesco
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.
2012-01-01 Barbui, T; Thiele, J; Passamonti, Francesco; Rumi, E; Boveri, E; Randi, Ml; Bertozzi, I; Marino, F; Vannucchi, Am; Pieri, L; Rotunno, G; Gisslinger, H; Gisslinger, B; Müllauer, L; Finazzi, G; Carobbio, A; Gianatti, A; Ruggeri, M; Nichele, I; D'Amore, E; Rambaldi, A; Tefferi, A.
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.
2012-01-01 Finazzi, G; Carobbio, A; Thiele, J; Passamonti, Francesco; Rumi, E; Ruggeri, M; Rodeghiero, F; Randi, Ml; Bertozzi, I; Vannucchi, Am; Antonioli, E; Gisslinger, H; Buxhofer Ausch, V; Gangat, N; Rambaldi, A; Tefferi, A; Barbui, T.
Improving survival trends in primary myelofibrosis: an international study.
2012-01-01 Cervantes, F; Dupriez, B; Passamonti, Francesco; Vannucchi, Am; Morra, E; Reilly, Jt; Demory, Jl; Rumi, E; Guglielmelli, P; Roncoroni, E; Tefferi, A; Pereira, A.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Multidisciplinary approach to bariatric surgery: surgical alternative of gastric banding | 1-gen-2002 | Gaeta, Luigi | |
| Dietary supplement and drug use and doping knowledge and attitudes in italian young elite cyclists | 1-gen-2014 | Loraschi, A.; Galli, N.; Cosentino, Marco | |
| Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. | 1-gen-2013 | Tefferi, A; Rumi, E; Finazzi, G; Gisslinger, H; Vannucchi, Am; Rodeghiero, F; Randi, Ml; Vaidya, R; Cazzola, M; Rambaldi, A; Gisslinger, B; Pieri, L; Ruggeri, M; Bertozzi, I; Sulai, Nh; Casetti, I; Carobbio, A; Jeryczynski, G; Larson, Dr; Müllauer, L; Pardanani, A; Thiele, J; Passamonti, Francesco; Barbui, T. | |
| Ruxolitinib and survival improvement in patients with myelofibrosis | 1-gen-2015 | Passamonti, Francesco; A. M., Vannucchi; F., Cervantes; C., Harrison; E., Morra; H., Kantarjian; S., Verstovsek | |
| Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project | 1-gen-2013 | G., Barosi; R., Mesa; G., Finazzi; C., Harrison; J. J., Kiladjian; E., Lengfelder; M. F., Mcmullin; Passamonti, Francesco; A. M., Vannucchi; C., Besses; H., Gisslinger; J., Samuelsson; S., Verstovsek; R., Hoffman; A., Pardanani; F., Cervantes; A., Tefferi; T., Barbui | |
| Use of the functional assessment of cancer therapy-anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia | 1-gen-2014 | Ayalew, Tefferi; Stacie, Hudgens; Ruben, Mesa; Robert Peter, Gale; Srdan, Verstovsek; Passamonti, Francesco; Francisco, Cervantes; Candido, Rivera; Tom, Tencer; Zeba M., Khan | |
| Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis | 1-gen-2013 | F., Cervantes; A. M., Vannucchi; J. J., Kiladjian; H. K., Al Ali; A., Sirulnik; V., Stalbovskaya; M., Mcquitty; D. S., Hunter; R. S., Levy; Passamonti, Francesco; T., Barbui; G., Barosi; C. N., Harrison; L., Knoops; H., Gisslinger | |
| Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report | 1-gen-2013 | A., Tefferi; F., Cervantes; R., Mesa; Passamonti, Francesco; S., Verstovsek; A. M., Vannucchi; J., Gotlib; B., Dupriez; A., Pardanani; C., Harrison; R., Hoffman; H., Gisslinger; N., Kroger; J., Thiele; T., Barbui; G., Barosi | |
| RBC-transfusion guidelines update | 1-gen-2012 | Gale, Rp; Barosi, G; Barbui, T; Cervantes, F; Dohner, K; Dupriez, B; Gupta, V; Harrison, C; Hoffman, R; Kiladjian, Jj; Mesa, R; Mc Mullin, Mf; Passamonti, Francesco; Ribrag, V; Roboz, G; Saglio, G; Vannucchi, A; Verstovsek, S. | |
| PDGFRB disease: right diagnosis to prolong survival | 1-gen-2014 | Passamonti, Francesco | |
| Novel agents in indolent lymphomas | 1-gen-2012 | Merli, M.; Ferrario, A.; Basilico, C.; Maffioli, M.; Caramazza, D.; Appio, L.; Arcaini, L.; Passamonti, Francesco | |
| New generation small-molecule inhibitors in myeloproliferative neoplasms | 1-gen-2012 | Passamonti, Francesco; Maffioli, M; Caramazza, D. | |
| Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs | 1-gen-2012 | Emanuel, R. M.; Dueck, A. C.; Geyer, H. L.; Kiladjian, J. J.; Slot, S.; Zweegman, S.; Te Boekhorst, P. A. W.; Commandeur, S.; Schouten, H. C.; Sackmann, F.; Fuentes, A. K.; Hernández Maraver, D.; Pahl, H. L.; Griesshammer, M.; Stegelmann, F.; Doehner, K.; Lehmann, T.; Bonatz, K.; Reiter, A.; Boyer, F.; Etienne, G.; Ianotto, J. C.; Ranta, D.; Roy, L.; Cahn, J. Y.; Harrison, C. N.; Radia, D.; Muxi, P.; Maldonado, N.; Besses, C.; Cervantes, F.; Johansson, P. L.; Barbui, T.; Barosi, G.; Vannucchi, A. M.; Passamonti, Francesco; Andreasson, B.; Ferarri, M. L.; Rambaldi, A.; Samuelsson, J.; Birgegard, G.; Tefferi, A.; Mesa, R. A. | |
| Looking for familial nodular lymphocyte-predominant Hodgkin lymphoma | 1-gen-2013 | Merli, M.; Maffioli, M.; Ferrario, A.; Passamonti, Francesco | |
| Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. | 1-gen-2012 | Verstovsek, S; Kantarjian, Hm; Estrov, Z; Cortes, Je; Thomas, Da; Kadia, T; Pierce, S; Jabbour, E; Borthakur, G; Rumi, E; Pungolino, E; Morra, E; Caramazza, D; Cazzola, M; Passamonti, Francesco | |
| Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients. | 1-gen-2012 | Buxhofer Ausch, V; Gisslinger, H; Thiele, J; Gisslinger, B; Kvasnicka, Hm; Müllauer, L; Frantal, S; Carobbio, A; Passamonti, Francesco; Rumi, E; Ruggeri, M; Rodeghiero, F; Randi, Ml; Bertozzi, I; Vannucchi, Am; Antonioli, E; Finazzi, G; Gangat, N; Tefferi, A; Barbui, T. | |
| Leukemia risk models in primary myelofibrosis: an International Working Group study. | 1-gen-2012 | Tefferi, A; Pardanani, A; Gangat, N; Begna, Kh; Hanson, Ca; Van Dyke, Dl; Caramazza, D; Vannucchi, Am; Morra, E; Cazzola, M; Pereira, A; Cervantes, F; Passamonti, Francesco | |
| Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. | 1-gen-2012 | Barbui, T; Thiele, J; Passamonti, Francesco; Rumi, E; Boveri, E; Randi, Ml; Bertozzi, I; Marino, F; Vannucchi, Am; Pieri, L; Rotunno, G; Gisslinger, H; Gisslinger, B; Müllauer, L; Finazzi, G; Carobbio, A; Gianatti, A; Ruggeri, M; Nichele, I; D'Amore, E; Rambaldi, A; Tefferi, A. | |
| Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. | 1-gen-2012 | Finazzi, G; Carobbio, A; Thiele, J; Passamonti, Francesco; Rumi, E; Ruggeri, M; Rodeghiero, F; Randi, Ml; Bertozzi, I; Vannucchi, Am; Antonioli, E; Gisslinger, H; Buxhofer Ausch, V; Gangat, N; Rambaldi, A; Tefferi, A; Barbui, T. | |
| Improving survival trends in primary myelofibrosis: an international study. | 1-gen-2012 | Cervantes, F; Dupriez, B; Passamonti, Francesco; Vannucchi, Am; Morra, E; Reilly, Jt; Demory, Jl; Rumi, E; Guglielmelli, P; Roncoroni, E; Tefferi, A; Pereira, A. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- Articoli su Riviste35263
Data di pubblicazione
- In corso di stampa26
- 2020 - 202710432
- 2010 - 201911845
- 2000 - 20097910
- 1990 - 19993628
- 1980 - 19891162
- 1970 - 1979252
- 1967 - 19698
Editore
- Edizioni Luigi Pozzi Srl:via Pana...51
- Japadre Editore, L'Aquila36
- WILEY34
- Elsevier BV:PO Box 211, 1000 AE A...31
- ELSEVIER SCIENCE BV29
- Franco Angeli Riviste SRL:viale M...28
- Springer Verlag Germany:Tiergarte...28
- -Roma: [s.n.]. -Artegierre-Esseze...26
- Elsevier B.V.23
- Royal Society of Chemistry:Thomas...21
Rivista
- PHYSICAL REVIEW LETTERS216
- LA RADIOLOGIA MEDICA180
- NUCLEAR INSTRUMENTS & METHODS IN ...176
- ASTRONOMY & ASTROPHYSICS168
- MONTHLY NOTICES OF THE ROYAL ASTR...165
- PLOS ONE163
- PHYSICS LETTERS. SECTION B154
- SCIENTIFIC REPORTS153
- THROMBOSIS AND HAEMOSTASIS145
- IL PROTAGORA140
Serie
- PROCEEDINGS OF INTERNATIONAL MATH...1
Keyword
- Humans1627
- Female817
- Male695
- Middle Aged526
- COVID-19518
- Aged481
- Adult464
- Italy345
- SARS-CoV-2317
- Treatment Outcome240
Lingua
- eng18885
- ita2906
- fre60
- spa55
- ger35
- por14
- bul9
- rus8
- gre6
- chi3
Accesso al fulltext
- no fulltext24730
- reserved5245
- open5085
- restricted107
- partially open93
- mixed2
- embargoed1